植入式静脉输液港感染相关影响因素的研究进展

摘要
图/表
参考文献(32)
相关文章 (15)

全文: PDF (597 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要植入式静脉输液港的使用可明显改善需要长期化疗患者的生活质量。自1982年首次报道使用以来，已越来越多地用于肿瘤患者的治疗。输液港相关并发症主要包括感染、血栓形成、导管功能障碍等，其中以输液港相关感染发生率最高。本文从输液港相关感染影响因素方面进行综述，以期为临床工作者采取有效的预防措施提供参考。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	余永刚朱卉娟厉周▲

关键词 ：植入式静脉输液港, 感染, 影响因素, 综述

Abstract：Use of implantable venous access port improves the quality of life of patients in need of long-term intravenous chemotherapy. Since the first implant of implantable venous access port performed in 1982, it has increasingly been used in the field of oncology treating. The major complications of implantable venous access port include infection, thrombosis, dysfunction and so on. Among these above, implantable venous access port related infection is the most prevalent complication. This paper reviews the risk factors of implantable venous access port related infection, aiming at providing reference for clinical staffs to take effective prevention measures.

Key words： Implantable venous access port Infection Risk factors Review

基金资助:广东省广州市产学研协同创新重大专项（20150 8020063）；
广东省医学科学技术研究基金项目（A2017412）。

通讯作者: ▲通讯作者

引用本文:

余永刚朱卉娟厉周▲. 植入式静脉输液港感染相关影响因素的研究进展[J]. 中国医药导报, 2019, 16(10): 41-44.
YU Yonggang ZHU Huijuan LI Zhou▲. Research progress on risk factors of implantable venous access port-related infection. 中国医药导报, 2019, 16(10): 41-44.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2019/V16/I10/41

[1] 黄建，王晓晨，于秀艳.植入式静脉输液港（浙江）临床应用多学科专家共识[J].实用肿瘤杂志，2018，33（1）：17-24.
[2] Lebeaux D，Fernandez-hidalgo N，Chauhan A，et al. Management of infections related to totally implantable venous-access ports：challenges and perspectives [J]. Lancet Infect Dis，2014，14（2）：146-159.
[3] Narducci F，Jean-Laurent M，Boulanger L，et al. Totally implantable venous access port systems and risk factors for complications：A one-year prospective study in a cancer centre [J]. Eur J Surg Oncol，2011，37（10）：913-918.
[4] Wang YC，Lin PL，Chou WH，et al. Long-term outcomes of totally implantable venous access devices [J]. Support Care Cancer，2017，25（7）：2049-2054.
[5] Wildgruber M，Lueg C，Borgmeyer S，et al. Polyurethane versus silicone catheters for central venous port devices implanted at the forearm [J]. Eur J Cancer，2016，59：113-124.
[6] Braun U，Lorenz E，Weimann C，et al. Mechanic and surface properties of central-venous port catheters after removal： A comparison of polyurethane and silicon rubber materials [J]. J Mech Behav Biomed Mater，2016，64：281-291.
[7] Loveday HP，Wilson JA，Pratt RJ，et al. epic3：National Evidence-Based Guidelines for Preventing Healthcare-Associated Infections in NHS Hospitals in England [J]. J Hosp Infect，2014，86（Suppl 1）：S1-S70.
[8] Hsieh CC，Weng HH，Huang WS，et al. Analysis of risk factors for central venous port failure in cancer patients [J]. World J Gastroentero，2009，15（37）：4709-4714.
[9] Zottele Bomfim GA，Wolosker N，Yazbek G，et al. Comparative Study of Valved and Nonvalved Fully Implantable Catheters Inserted Via Ultrasound-Guided Puncture for Chemotherapy [J].Ann Vasc Surg，2014，28（2）：351-357.
[10] Hsu JF，Chang HL，Tsai MJ，et al. Port type is a possible risk factor for implantable venous access port-related bloodstream infections and no sign of local infection predicts the growth of gram-negative bacilli [J]. World J Surg Oncol，2015，13：288
[11] Penel N，Neu JC，Clisant S，et al. Risk factors for early catheter-related infections in cancer patients [J]. Cancer，2007，110（7）：1586-1592.
[12] Jenssen C，Brkljacic B，Hocke M，et al. EFSUMB Guidelines on Interventional Ultrasound（INVUS），Part Ⅵ Ultrasound-Guided Vascular Interventions [J]. Ultraschall Med，2016，37（5）：473-476.
[13] Pandey N，Chittams JL，Trerotola SO. Outpatient Placement of Subcutaneous Venous Access Ports Reduces the Rate of Infection and Dehiscence Compared with Inpatient Placement [J]. J Vasc Interv Radiol，2013，24（6）：849-854.
[14] Zerati AE，Figueredo TR，De Moraes RD，et al. Risk factors for infectious and noninfectious complications of totally implantable venous catheters in cancer patients [J]. J Vasc Surg Venous Lymphat Disord，2016，4（2）：200-205.
[15] Li YH，Cai YH，Gan XQ，et al. Application and comparison of different implanted ports in malignant tumor patients [J]. World J Surg Oncol，2016，14（1）：251.
[16] Shiono M，Takahashi S，Kakudo Y，et al. Upper Arm Central Venous Port Implantation：A 6-Year Single Institutional Retrospective Analysis and Pictorial Essay of Procedures for Insertion [J]. PLoS One，2014，9（3）：e91335.
[17] 徐海萍，周琴，韩伟，等.手臂输液港与胸壁输液港常见并发症发生率比较的Meta分析[J].中华护理杂志，2018， 53（3）：352-358.
[18] Ji L，Yang J，Miao J，et al. Infections Related to Totally Implantable Venous-Access Ports：Long-Term Experience in One Center [J]. Cell Biochem Biophys，2015，72（1）：235-240.
[19] Wang TY，Lee KD，Chen PT，et al. Incidence and risk factors for central venous access port-related infection in Chinese cancer patients [J]. J Formos Med Assoc，2015， 114（11）：1055-1060.
[20] Shim J，Seo TS，Song MG，et al. Incidence and Risk Factors of Infectious Complications Related to Implantable Venous-Access Ports [J]. Korean J Radiol，2014，15（4）：494-500.
[21] Toure A，Vanhems P，Lombard-Bohas C，et al. Is diabetes a risk factor for central venous access port-related bloodstream infection in oncological patients? [J]. Eur J Clin Microbiol，2013，32（1）：133-138.
[22] Dal Molin A，Di Massimo DS，Braggion C，et al. Totally implantable central venous access ports in patients with cystic fibrosis：a multicenter prospective cohort study [J]. J Vasc Access，2012，13（3）：290-295.
[23] Astagneau P，Maugat S，Tran-Minh T，et al. Long-term central venous catheter infection in HIV-infected and cancer patients：a multicenter cohort study [J]. Infect Control Hosp Epidemiol，1999，20（7）：494-498.
[24] Toure A，Vanhems P，Lombard-Bohas C，et al. Totally implantable central venous access port infections in patients with digestive cancer：Incidence and risk factors [J]. Am J Infect Control，2012，40（10）：935-939.
[25] Lee GJ，Hong SH，Roh SY，et al. A Case-Control Study to Identify Risk Factors for Totally Implantable Central Venous Port-Related Bloodstream Infection [J]. Cancer Res Treat，2014，46（3）：250-260.
[26] Gapany C，Tercier S，Diezi M，et al. Frequent accesses to totally implanted vascular ports in pediatric oncology patients are associated with higher infection rates [J]. J Vasc Access，2011，12（3）：207-210.
[27] 中心静脉通路上海协作组.完全植入式输液港上海专家共识[J].介入放射学杂志，2015，24（12）：1029-1033.
[28] Kakkos A，Bresson L，Hudry D，et al. Complication-related removal of totally implantable venous access port systems：Does the interval between placement and first use and the neutropenia-inducing potential of chemotherapy regimens influence their incidence？A four-year prospective study of 4045 patients [J]. Eur J Surg Oncol，2017，43（4）：689-695.
[29] Young SJ，Young LJ，Vogel J，et al. Accessing totally implantable venous access systems on the day of placement does not significantly increase the risk of infection [J]. J Vasc Access，2016，17（3）：261-264.
[30] Karanlik H，Odabas H，Yildirim I，et al. Is there any effect of first-day usage of a totally implantable venous access device on complications？[J]. Int J Clin Oncol，2015，20（6）：1057-1062.
[31] Toure A，Chambrier C，Vanhems P，et al. Propensity score analysis confirms the independent effect of parenteral nutrition on the risk of central venous catheter-related bloodstream infection in oncological patients [J]. Clin Nutr，2013，32（6）：1050-1054.
[32] Pontes-Arruda A，Liu FX，Turpin RS，et al. Bloodstream Infections in Patients Receiving Manufactured Parenteral Nutrition With vs Without Lipids： Is the Use of Lipids Really Deleterious？[J]. Jpen J Parenter Enteral Nutr，2012，36（4）：421-430.